(Q38089834)

28 August 2017

title

Malignant glioma drug discovery - targeting protein kinases (English)

1 reference

28 August 2017

1 reference

4

Jeremy N Rich

1 reference

28 August 2017

Sith Sathornsumetee

1

1 reference

28 August 2017

Kaitlyn A Vredenburgh

series ordinal

2

1 reference

28 August 2017

Kathryn P Lattimore

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Drug Discovery

28 August 2017

published in

1 reference

28 August 2017

volume

2

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

1-17

1 reference

A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Signal events: Cell signal transduction and its inhibition in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Signal transduction pathways and their relevance in human astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

The protein tyrosine kinase family of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

EGF-ERBB signalling: towards the systems level

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

EGFR mutations and sensitivity to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

EGFR tyrosine kinase domain mutations in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Platelet-derived growth factor (PDGF) and glial tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

The insulin-like growth factor-I receptor as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Intracellular signal transduction pathway proteins as targets for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Reduced glioma infiltration in Src-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Gene expression profiling and genetic markers in glioblastoma survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Cooperative translational control of gene expression by Ras and Akt in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Targeting Raf-kinase: molecular rationales and translational issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Development of farnesyl transferase inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Oncogenic PI3K deregulates transcription and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

The molecular heterogeneity of protein kinase C and its implications for cellular regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

The ubiquitin-proteasome pathway and its role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Hsp90: chaperoning signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Comparing antibody and small-molecule therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Strategies for optimizing combinations of molecularly targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

EphA2 as a glioma-associated antigen: a novel target for glioma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Ephrin-B3 ligand promotes glioma invasion through activation of Rac1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Increased human polo-like kinase-1 expression in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Response of glioblastomas to EGFR kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

Circumventing Resistance to Kinase-Inhibitor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2.1.1

21 January 2018

Identifiers

DOI

10.1517/17460441.2.1.1

1 reference

28 August 2017

1 reference